Literature DB >> 15509628

Prospects for B-cell-targeted therapy in autoimmune disease.

J C W Edwards1, G Cambridge.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15509628     DOI： 10.1093/rheumatology/keh446

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN： 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  17 in total

Review 1.  How does B cell depletion therapy work, and how can it be improved?

Authors:  E A Clark; J A Ledbetter
Journal:  Ann Rheum Dis       Date:  2005-11       Impact factor: 19.103

2.  Efficacy of B cell depletion in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor alpha agents: an open-label observational study.

Authors:  L Brulhart; A Ciurea; A Finckh; A Notter; J M Waldburger; D Kyburz; C Gabay
Journal:  Ann Rheum Dis       Date:  2006-03-15       Impact factor: 19.103

3.  Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression.

Authors:  Takashi Matsushita; Koichi Yanaba; Jean-David Bouaziz; Manabu Fujimoto; Thomas F Tedder
Journal:  J Clin Invest       Date:  2008-10       Impact factor: 14.808

4.  B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis.

Authors:  Minoru Hasegawa; Yasuhito Hamaguchi; Koichi Yanaba; Jean-David Bouaziz; Junji Uchida; Manabu Fujimoto; Takashi Matsushita; Yukiyo Matsushita; Mayuka Horikawa; Kazuhiro Komura; Kazuhiko Takehara; Shinichi Sato; Thomas F Tedder
Journal:  Am J Pathol       Date:  2006-09       Impact factor: 4.307

5.  Therapeutic B cell depletion impairs adaptive and autoreactive CD4+ T cell activation in mice.

Authors:  Jean-David Bouaziz; Koichi Yanaba; Guglielmo M Venturi; Yaming Wang; Roland M Tisch; Jonathan C Poe; Thomas F Tedder
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-19       Impact factor: 11.205

6.  Targeting lentiviral vectors to antigen-specific immunoglobulins.

Authors:  Leslie Ziegler; Lili Yang; Kye il Joo; Haiguang Yang; David Baltimore; Pin Wang
Journal:  Hum Gene Ther       Date:  2008-09       Impact factor: 5.695

7.  B-cell depletion in patients with rheumatoid arthritis refractant to multiple TNF blockers and the interleukin 1 receptor-antagonist anakinra. Good responses in an extreme negative selection.

Authors:  J C Henes; C Richter; L Kanz; I Koetter
Journal:  Rheumatol Int       Date:  2007-06-12       Impact factor: 2.631

8.  A case of Rasmussen encephalitis treated with rituximab.

Authors:  Barbara Thilo; Robert Stingele; Karina Knudsen; Rainer Boor; Christian G Bien; Günther Deuschl; Nicolas Lang
Journal:  Nat Rev Neurol       Date:  2009-08       Impact factor: 42.937

Review 9.  Anti-neutrophil cytoplasmic (ANCA) and anti-glomerular basement membrane (GBM) autoantibodies in necrotizing and crescentic glomerulonephritis.

Authors:  Sofia Lionaki; J Charles Jennette; Ronald J Falk
Journal:  Semin Immunopathol       Date:  2007-10-18       Impact factor: 9.623

10.  Treatment of neuromyelitis optica with rituximab: a 2-year prospective multicenter study.

Authors:  Philippe Cabre; M Mejdoubi; S Jeannin; H Merle; Y Plumelle; G Cavillon; D Smadja; R Marignier
Journal:  J Neurol       Date:  2018-02-17       Impact factor: 4.849
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.